361 Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

361 Capital’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-24,874	Closed	-$409K	–	280
2017 Q2	$409K	Buy	24,874 +11,904	+92%	+$184K	0.07%	146
2017 Q1	$186K	Buy	+12,970	New	+$192K	0.04%	150

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UIM

USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

361 Capital's LXRX Position: Q3 2017 in Review

361 Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2017, closing a stake of 24,874 shares — an estimated $409K sold.

361 Capital first reported a position in LXRX in Q1 2017 and held it in 2 quarters. The position peaked at $409K in Q2 2017. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2017.

361 Capital reported no remaining Lexicon Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
361 Capital sold 24,874 Lexicon Pharmaceuticals shares in Q3 2017, an estimated $409K.
361 Capital first reported a position in Lexicon Pharmaceuticals in Q1 2017 and held it in 2 quarters.
361 Capital's Lexicon Pharmaceuticals position peaked at $409K in Q2 2017.
137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2017.

Based on 361 Capital's 13F filing for Q3 2017, filed 7 Nov 2017.